Drug News

Global IV & Oral Iron Drugs Market Report 2024: Market to Reach $16.43 Billion by 2029

Research and Markets has released a report titled “Global IV & Oral Iron Drugs Market – Focused Insights 2024-2029” offering comprehensive analysis and forecasts for the IV and oral iron drugs market.

Market Overview: The global IV and oral iron drugs market, valued at $7.66 billion in 2023, is projected to experience robust growth, reaching $16.43 billion by 2029, with a notable compound annual growth rate (CAGR) of 13.47%. This surge is primarily driven by the increasing prevalence of Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) globally, alongside heightened patient awareness regarding effective treatment options.

Key Growth Drivers:

  • Prevalence of Chronic Diseases: Rising occurrence of chronic diseases like Chronic Kidney Disease (CKD), heart failure, gastrointestinal disorders, and cancer contribute to iron deficiency, particularly in surgical patients.
  • Demand for Dextran-Free Iron Therapeutics: Growing demand for dextran-free iron therapeutics propels market growth.
  • Innovations in IV & Oral Iron Drugs: Development of investigational latest generation IV & oral iron drugs with broader indications and improved treatment outcomes fuels market expansion.

Market Dynamics:

  • Route of Administration: The intravenous iron segment, valued at $4.40 billion in 2023, is expected to witness significant growth due to expanded indication approval for existing brands and expected launch of branded IV iron drugs in new markets.
  • Patient Group: The adult segment dominates the market, accounting for 83.33% in 2023, attributed to higher incidence/prevalence of ID and IDA among the elderly.
  • Distribution Channel: Hospital pharmacies segment is poised for significant growth, offering cost-effective options with discounts and rebates.
  • Application: Nephrology segment accounted for 60.84% in 2023, driven by increasing uptake of iron drugs to treat CKD.

Key Players:

  • Market Dominance: CSL Vifor, Covis Pharmaceuticals, Daiichi Sankyo, Akebia Therapeutics, Shield Therapeutics are among the leading players dominating the market.
  • Strategic Focus: Major players focus on strategic acquisitions and collaborations with emerging players to enter the IV & Oral Iron Drugs market and gain access to commercially launched products.

Market Structure: The report provides insights into market dynamics, competitive landscape, key vendors, and product segmentation & forecast, covering route of administration, patient group, distribution channel, and application.

Vendors List: Key vendors include CSL Vifor, Daiichi Sankyo, Covis Pharmaceuticals, Akebia Therapeutics, Shield Therapeutics, along with other prominent players such as Pharmacosmos, AbbVie, Sanofi, Pfizer, and more.

Conclusion: The global IV & Oral Iron Drugs market demonstrates significant growth potential driven by increasing prevalence of iron deficiency globally, rising demand for effective treatment options, and innovations in IV & oral iron drugs. Key players are strategically positioning themselves to capitalize on emerging opportunities and address evolving patient needs.

Source: PRNewswire


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker